

26 June 2023

New Biologic and Targeted Medications in Dermatology and Respiratory Medicine

I am analysing the usage of new biologic and targeted medications within Dermatology and Respiratory medicine. Could you please answer the following questions?

1. How many patients were treated in May 2023 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo) <5
- Baricitinib (Olumiant) <5
- Dupilumab (Dupixent) 135
- Omalizumab (Xolair) 24
- Tralokinumab (Adtralza) <5
- Upadacitinib (Rinvoq) 14

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. How many patients were treated in May 2023 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra) 98 (63 on homecare) – patients treated every 8 weeks – so this would cover a 2-month period as too timely to work out exactly for May 2023
- Dupilumab (Dupixent) 43 (32 on homecare) – every 2 weeks
- Mepolizumab (Nucala) 237 (179 on homecare) – every 4 weeks
- Omalizumab (Xolair) 22 every 2 or 4 weeks
- Reslizumab (Cinqaero) 3 every 4 weeks
- Tezepelumab (Tezspire) None